Fig. 3. Improved clinical responses to CD19 CAR-T cell immunotherapy after Cy/Flu lymphodepletion. Improved clinical responses to CD19 CAR-T cell immunotherapy.

Slides:

Advertisements

Similar presentations

T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia by Michael Kalos, Bruce.

Advertisements

Fig. 1 Kaplan–Meier curves of post-progression survival (PPS) in the docetaxel and best supportive care (BSC) groups. Median PPS was 5.4 months in the.

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab Tomoko Funazo,

CD25 expression is associated with unfavorable clinical outcome.

Comparison of the model incorporating daily dose to that incorporating Cmax. Comparison of the model incorporating daily dose to that incorporating Cmax.

Fig. 2 LYM attractor metagene.

Fig. 5. Correlation between CD34+CD45RA−CD90+ cell dose, engraftment success, and onset of neutrophil/platelet recovery in nonhuman primates. Correlation.

Fig. 2. Engraftment of CART-EGFRvIII and cytokine modulation in the peripheral blood. Engraftment of CART-EGFRvIII and cytokine modulation in the peripheral.

Fig. 8. In vivo suppression of MM by CMLD

A B Yeom Supplementary Fig.2

CAR8 failure in an OT1 TCR transgenic T cell after exposure to OVA

Fig. 5. Serum VEGF-C correlates with antitumor immune responses and PFS after immunotherapy in human metastatic melanoma patients. Serum VEGF-C correlates.

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab Tomoko Funazo,

Persistence of CAR4 cells is reduced after sustained TCR engagement

Fig. 4. Restriction of TCR antigen to hematopoietic tissues does not prevent CAR8 exhaustion and failure of leukemia clearance. Restriction of TCR antigen.

Fig. 7 BRD0705 impairs colony formation in AML cell lines and patient cells and shows in vivo efficacy in multiple AML mouse models. BRD0705 impairs colony.

Kaplan-Meier curves for overall survival (OS) probability.

Comparison of therapeutic efficacies of C12G6 and other bnAbs in mice

CD facilitates RCT in vivo and promotes urinary cholesterol excretion

Evaluation of clinical responses after infusion of CART19 cells

Fig. 2. Increased CD19 CAR-T cell expansion and persistence after Cy/Flu lymphodepletion. Increased CD19 CAR-T cell expansion and persistence after Cy/Flu.

Fig. 6 In utero injection of inflammatory cytokines or adoptive transfer of activated T cells leads to pregnancy loss. In utero injection of inflammatory.

Fig. 4. Peanut-specific TH2A cells are specifically targeted during immunotherapy. Peanut-specific TH2A cells are specifically targeted during immunotherapy.

Fig. 3. The effect of VRC01 infusion on virus load in plasma and blood CD4 T cells during ART. The effect of VRC01 infusion on virus load in plasma and.

Consolidated Standards of Reporting Trials flow diagram of VRC trial

Fig. 2. Clinically actionable somatic genomic alterations in various tumor types. Clinically actionable somatic genomic alterations in various tumor types.

Davide Capodanno et al. JCIN 2009;2:

Fig. 1. Schematic showing the shedding of tumor DNA from head and neck cancers into the saliva or plasma. Schematic showing the shedding of tumor DNA from.

Fig. 6. TIV-09, but not MIV-09, induces an IFN signature in the blood of vaccinated individuals at day 1. TIV-09, but not MIV-09, induces an IFN signature.

Increase in adults treated at children's hospitals, 1999–2012, according to age group. Increase in adults treated at children's hospitals, 1999–2012, according.

Fig. 3 ROC curves of mCCNA1 and mVIM assayed in esophageal cytology brushings from control normal-appearing GE junctions versus BE and EAC cases. ROC curves.

Fig. 3 Liver stiffness and NT-proBNP concentration after treatment with miridesap followed by dezamizumab. Liver stiffness and NT-proBNP concentration.

Fig. 3 NK cells are enriched in ICB-sensitive tumors in mouse models and patients and are required for response. NK cells are enriched in ICB-sensitive.

Fig. 2 LYM attractor metagene.

Fig. 2. Bacterial/viral score in COCONUT-conormalized whole-blood validation data sets. Bacterial/viral score in COCONUT-conormalized whole-blood validation.

Fig. 5. Vitamin B12 supplementation in the host altered the transcriptome of P. acnes in the skin microbiota. Vitamin B12 supplementation in the host altered.

Fig. 1. CAR4 and CAR8 cells demonstrate in vitro and in vivo antileukemic efficacy. CAR4 and CAR8 cells demonstrate in vitro and in vivo antileukemic efficacy.

Fig. 2. In vitro activity of DSM265 and its analogs on DHODH and P

Survival based on V gene mutation status and CD38 expression among B-CLL patients who stratify to the Rai intermediate risk category. Survival based on.

BMS blocks functional responses in primary immune cells driven by IFNα

Fig. 1. Detection of circulating tumor DNA in CRPC patients.

Fig. 4. Long-term persistence of CTL019 cells and polyfunctionality in patients achieving CR. Long-term persistence of CTL019 cells and polyfunctionality.

The microchip-based drug delivery device and overview of study design

Fig. 2. Mutational signature exposures in Taiwan HCCs and summary of AA signature mutations. Mutational signature exposures in Taiwan HCCs and summary.

MiR-520d-3p is an independent positive prognostic factor in ovarian cancer. miR-520d-3p is an independent positive prognostic factor in ovarian cancer.

Fig. 2 PK dosing results. PK dosing results. (A) Plasma concentration of hPTH(1–34) versus time after release of 40-μg dose from implanted microchip device.

CD8, galectin-3, galectin-9, and the M1/M2 ratio are associated with a longer survival. CD8, galectin-3, galectin-9, and the M1/M2 ratio are associated.

Kaplan–Meier curves for PFS and OS (for patients treated with anti-PD-1/PD-L1 monotherapy). Kaplan–Meier curves for PFS and OS (for patients treated with.

Fig. 2. PlGF-2123–144 conjugation reduces systemic exposure to checkpoint blockade Abs and potential treatment-related toxicity. PlGF-2123–144 conjugation.

Progression-free (a) and overall (b) survival by age subgroup, Kaplan-Meier plots. Progression-free (a) and overall (b) survival by age subgroup, Kaplan-Meier.

Fig. 8. Purkinje cell quantification and hearing threshold in NPC cats administered IC HPβCD. Purkinje cell quantification and hearing threshold in NPC.

The ROC curves analyzing the sensitivity and specificity of rCBVmax values in astrocytomas for 1-year survival (A) and recurrence (B) show the optimal.

A and B, The ROC curves analyzing the sensitivity and specificity of the WHO grading system (I-IV) for the 1-year survival (A) and recurrence (B) show.

Evaluation of clinical responses after infusion of CART19 cells

Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia by David L. Porter, Wei-Ting.

Fig. 5 Increased myometrial cell contractility in response to fetal T cells from preterm infants. Increased myometrial cell contractility in response to.

In vivo prophylactic and therapeutic efficacy of C12G6 in mice

T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia by Michael Kalos, Bruce.

miR can promote cardiomyocyte proliferation in the adult heart

Fig. 5 Proportions of EpCAM+ systemic tumor cells correlate with the clinical outcome of patients with MBC. Proportions of EpCAM+ systemic tumor cells.

Fig. 5. High burdens of AA signature mutations and predicted immunogenicity in Taiwan HCCs. High burdens of AA signature mutations and predicted immunogenicity.

Schedule-dependent impact of costimulated activated T-cell transfer on T-cell reconstitution after tandem stem cell transplant. Schedule-dependent impact.

Fig. 3. miR overexpression leads to increased cell proliferation as well as altered differentiation and metabolism in cardiomyocytes. miR

Fig. 3 Superiority of BAFF-R versus CD19-CAR T cells in a Burkitt lymphoma model is not due to greater tumor antigen density. Superiority of BAFF-R versus.

TMEscore is a prognostic biomarker and predicts immunotherapeutic benefit. TMEscore is a prognostic biomarker and predicts immunotherapeutic benefit. A,

Fig. 3. Association between peak CTL019 expansion and response.

Systemic inflammation in patients with severe neurotoxicity (NTX).

Fig. 3 Postnatal assembly of the humanized gut microbiota.

Fig. 5 CD19-tPSMA(N9del) CAR T cell numbers in mouse and human.

Fig. 2. In vivo local CD25-targeted NIR-PIT induces regression of treated LL/2-luc tumors. In vivo local CD25-targeted NIR-PIT induces regression of treated.

Presentation transcript:

Fig. 3. Improved clinical responses to CD19 CAR-T cell immunotherapy after Cy/Flu lymphodepletion. Improved clinical responses to CD19 CAR-T cell immunotherapy after Cy/Flu lymphodepletion. (A and B) Mean ± SEM of CD4+/EGFRt+ (A) and CD8+/EGFRt+ (B) CAR-T cell counts in the blood on the indicated days after CAR-T cell infusion for patients treated with Cy/Flu lymphodepletion and either 2 × 105 or 2 × 106 EGFRt+ cells/kg. (C) CAR-T cell persistence in the blood as integrated transgene copies per microgram of DNA in two patients who received a cycle of Cy/Flu lymphodepletion chemotherapy and CAR-T cell infusion followed by a second cycle of Cy/Flu lymphodepletion chemotherapy and CAR-T cell infusion. (D) Probability curves showing the likelihood of response (CR/PR) according to the peak CD4+/EGFRt+ and CD8+/EGFRt+ cell counts in blood, the AUC0–28, and Cmax. P values were reported from the Wilcoxon two-sample test. (E and F) OS and PFS for patients who received Cy/Flu compared to Cy or Cy/E (No Flu) lymphodepletion followed by infusion of CD19 CAR-T cells at ≤2 × 106 EGFRt+ cells/kg. The median OS follow-up times for No Flu and Cy/Flu are 25 and 6.3 months, respectively. The median PFS follow-up for Cy/Flu is 5.8 months. The median PFS for No Flu is 1.5 months. The numbers of patients at risk at each time point are indicated. Log-rank tests were used to compare between-group differences in survival curves. HR, hazard ratio; CI, confidence interval. Cameron J. Turtle et al., Sci Transl Med 2016;8:355ra116 Copyright © 2016, American Association for the Advancement of Science